Last reviewed · How we verify
ABP 980
ABP 980 is a HER2-targeting antibody-drug conjugate that delivers cytotoxic payload to HER2-expressing cancer cells.
ABP 980 is a HER2-targeting antibody-drug conjugate that delivers cytotoxic payload to HER2-expressing cancer cells. Used for HER2-positive gastric cancer, HER2-positive breast cancer.
At a glance
| Generic name | ABP 980 |
|---|---|
| Sponsor | Amgen |
| Drug class | Antibody-drug conjugate (ADC) |
| Target | HER2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
ABP 980 binds to HER2 receptors on cancer cells and is internalized, releasing a microtubule-disrupting payload (similar to trastuzumab deruxtecan mechanism). This dual targeting approach aims to improve efficacy and potentially overcome resistance seen with earlier HER2-directed therapies.
Approved indications
- HER2-positive gastric cancer
- HER2-positive breast cancer
Common side effects
- Nausea
- Fatigue
- Diarrhea
- Vomiting
- Neutropenia
Key clinical trials
- Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J) (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
- CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy (PHASE2)
- Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery (PHASE2)
- Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer (PHASE1, PHASE2)
- TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer (PHASE2)
- An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis (PHASE4)
- Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABP 980 CI brief — competitive landscape report
- ABP 980 updates RSS · CI watch RSS
- Amgen portfolio CI